Treatment of mild to moderate alopecia areata with compound glycyrrhizin: a randomized controlled trial

Treatment of mild to moderate active alopecia areata with compound glycyrrhizin: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800018691

Enrollment

Unknown

Registered

2018-10-04

Start date

2015-09-01

Completion date

Unknown

Last updated

2018-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

alopecia areata

Interventions

Group 1:two 25-mg oral tablets of compound glycyrrhizin three times per day and topical 0.05% halometasone cream locally twice daily

Group 2:topical 0.05% halometasone cream locally twice daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Consistent with AA diagnosis; 2. Presenting with patchy AA; 3. Area of alopecia <50%; 4. Hair-pull test (+); 5. Aged 18 to 65 years.

Exclusion criteria

Exclusion criteria: (1) Area of alopecia=50%; (2) ophiasis AA; (3) Hair-pull test (-); (4) Allergic or contraindications for compound glycyrrhizin; (5) Pregnant or nursing; (6) Presenting with immunodeficiency systemic diseases; (7) Presenting with other inflammatory or autoimmune skin diseases; (8) Received systemic corticosteroids, compound glycyrrhizins or other biological agents within the previous 4 weeks; (9) Received topical/local injection of corticosteroids, topical minoxidil, or contact immunotherapy treatment within the previous one week.

Design outcomes

Primary

Measure	Time frame
SALT score;Alopecia areata disease activity;Clinical efficacy;	—

Countries

China

Contacts

Public ContactYang Qinping

Huashan Hospital, Fudan University

dxq93216@163.com+86 13601927866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026